Q-omics provides the consensus-scored CSNK1G2P1 profile across patient tissues and cancer cell-line models. CSNK1G2P1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CSNK1G2P1 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, CSNK1G2P1 RNA expression shows 12,692 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, THCA, and UVM as cancer lineages where CSNK1G2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSNK1G2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSNK1G2P1 survival associations across molecular data types. CSNK1G2P1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSNK1G2P1 RNA expression–survival associations across cancer types. High CSNK1G2P1 expression shows unfavorable associations in ACC and KICH, but favorable associations in HNSC, UCS, STAD and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CSNK1G2P1 RNA expression.
This table summarizes CSNK1G2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CSNK1G2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSNK1G2P1 shows lower tumor expression in THCA and higher tumor expression in CHOL and STAD. The THCA box plot shows higher CSNK1G2P1 RNA expression in normal versus tumor tissue (log2 FC = −0.075, t-test p < 0.001).
This table shows molecular features associated with CSNK1G2P1 in patient tissues and cancer cell lines. In patient samples, CSNK1G2P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
